Hepatocellular Carcinoma – Opportunity Analysis and Forecasts to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The hepatocellular carcinoma (HCC) market is expected to grow from $1.4bn in 2019 to $5.5bn in 2029 in the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 14.5%. The significant growth in the therapy market is driven by implementing new strategies such as developing combinations of therapies with different mechanism of actions, label expansion of marketed therapies for HCC into earlier lines of therapy, and label expansion of drugs approved in other indications into HCC.
Mandana Emamzadeh, PhD, Pharma Analyst at GlobalData, comments: “The treatment landscape of HCC is rapidly changing and it is hoped that the numerous clinical trials due to report in the near future will expand treatment options across adjuvant, intermediate, and advanced settings.”
GlobalData’s report highlights nine late-stage pipeline therapies for HCC that will enter the market by 2029. In early- and intermediate-stage HCC, systemic therapies used as adjuvant treatment or as combinations with transcatheter arterial chemoembolization (TACE), respectively, are seeking to introduce new options to the HCC paradigm where currently none exist. Within the advanced setting, the majority of trials are for the first-line setting and a few are in the second line, creating a competitive market.
Emamzadeh explains: “By 2029, first-line advanced HCC, with $2.7bn global sales, is forecast to be the most profitable line of therapy due to the highest number of treated cases, as well as the relatively high cost of treatment in this setting, which decreases in subsequent lines of therapy. With fewer treated cases, sales in the intermediate, second-line advanced, adjuvant, and third-line advanced settings are $1.8bn, $562.6m, $307.7m, and $115.0m, respectively.”
IO agents will be the dominant class in the HCC market contributing $3.8bn, followed by angiogenesis inhibitors and TKI contributing $975.0m and $716.5m to global sales in 2029, respectively.
Emamzadeh concludes: “Between 2019 and 2029, barriers such as patent expiry of key drugs will depreciate the market value with the emergence of generics and biosimilars of the top-selling brands, including Bayer’s Nexavar, Eisai’s Lenvima, and Roche’s Avastin. Despite this, the market is growing at an impressive rate and opportunities exist for developers to further improve the HCC treatment landscape.”
*8MM: US, France, Germany, Italy, Spain, UK, Japan, and China
KEY QUESTIONS ANSWERED
• Which unmet needs are limiting the treatment of hepatocellular carcinoma in the 8MM?
• What strategies can the pharmaceutical industry employ to increase treatment rates for hepatocellular carcinoma? How should these strategies differ across different geographical markets?
• What effect will the launch of biosimilars and generics have on the sales of branded agents?
• What are the main R&D trends in the hepatocellular carcinoma market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
Scope
Overview of HCC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline HCC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HCC therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global HCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
Upon approval of Avastin + Tecentriq by the FDA, in May 2020, the combination replaced the SoC in first-line advanced HCC, shifting Nexavar and Lenvima to second-line treatment options.
The greatest drivers of growth in the global HCC market include the launch of new pipeline therapies, combinations of therapies with different MOAs, label expansion from other oncology indications to HCC, and label expansion into earlier lines of therapy, in addition to an increase in diagnosed incident cases in many 8MM countries.
The main barrier to growth in the HCC market is patent expiration of key biologic brands with subsequent biosimilar launch.
The most important unmet needs in the HCC market are better HCC surveillance and prophylactic treatments, curative therapies in early-stage HCC, improved survival for intermediate-stage HCC, data on sequencing of treatments, prognostic biomarkers, treatments for patients with impaired liver function.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global HCC therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global HCC therapeutics market from 2019-2029.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Bayer
BMS
Onyx Pharmaceuticals
Eisai
Exelixis
Roche/Genentech
Merck & Co.
Novartis
Ono
ImClone Systems
Suzhou Zelgen Biopharmaceutical
Jiangsu Hengrui Medicine
BeiGene Ltd
CStone Pharmaceuticals Co
Innovent Biologics
Shanghai Junshi Bioscience
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.